<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391481</url>
  </required_header>
  <id_info>
    <org_study_id>PLAGH-PFC</org_study_id>
    <nct_id>NCT01391481</nct_id>
  </id_info>
  <brief_title>Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome</brief_title>
  <official_title>The Randomized Controlled Trial (RCT) on the Vaporized Perfluorocarbon (PFC) Inhalation Treatment of Acute Respiratory Distress Syndrome With the Invasive Mechanical Ventilation（IMV）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Artillery General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 306 Hospital of People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospitals affiliated to the China PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Chinese Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital, Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Air Force General Hospital of the PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>309th Hospital of Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PFCs (perfluorocarbons, PFC), an ideal liquid respiratory media, has special chemical and&#xD;
      biological properties, including high solubility of gas, swiftness of carrying and release,&#xD;
      low surface tension, high proportion, almost non-absorbing and non-metabolic characteristics&#xD;
      in the body. On the basis of the strong animal data suggesting the efficacy of PFC vapor&#xD;
      inhalation in models of lung injury, we performed a randomized clinical trial comparing PFC&#xD;
      vapor inhalation with conventional mechanical ventilation（CMV）in patients with Acute Lung&#xD;
      Injury/Acute Respiratory Distress Syndrome（ALI/ARDS）. The investigators will apply the&#xD;
      Invasive Mechanical Ventilation (IMV) to the vaporized perfluorocarbon inhalation,&#xD;
      objectively evaluate its curative effect on the acute respiratory distress syndrome, and&#xD;
      meanwhile assess the safety of PFC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the invasive mechanical ventilation (IMV) treatment of ALI/ARDS, the therapeutic&#xD;
      action of vaporized PFC inhalation will be evaluated on the treatment of ALI/ARDS patients,&#xD;
      and the safety of vaporized PFC inhalation on the treatment of ALI/ARDS. The Test group will&#xD;
      make a timing and fix quantify inhalation of PFC, while the control group will be treated&#xD;
      with the inhalation of water for injection. The general condition of patients will be&#xD;
      assessed by monitoring their vital signs, hematology testing and APACHE II score, etc. Main&#xD;
      outcome measures include the oxygenation index, respiratory mechanics; secondary outcomes&#xD;
      include ventilator-free days, 28-day mortality and so on.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxygenation index, respiratory mechanics</measure>
    <time_frame>three years</time_frame>
    <description>oxygenation index and respiratory mechanics will be abtained before and 1, 2, 4h after every inhalation,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>three years</time_frame>
    <description>ventilator-free days, 28-day mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <condition>Acute Lung Injury</condition>
  <arm_group>
    <arm_group_label>Perfluorocarbon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Water for Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perfluorocarbon</intervention_name>
    <description>Vaporized PFC Inhalation 100ml/8h for 5 days</description>
    <arm_group_label>Perfluorocarbon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Water for Injection</intervention_name>
    <description>Inhalation of Sterile Water for Injection, 100ml/8h for 5 days</description>
    <arm_group_label>Sterile Water for Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-75 years old&#xD;
&#xD;
          -  Some clear risk aetiological agents of acute respiratory distress syndrome&#xD;
&#xD;
          -  Acute onset, with corresponding clinical manifestations&#xD;
&#xD;
          -  PaO2/FiO2 ≤ 300mmHg&#xD;
&#xD;
          -  Chest radiograph or chest computerized tomography prompting bilateral pulmonary&#xD;
             infiltrate shadow&#xD;
&#xD;
          -  pulmonary capillary wedge pressure (PCWP) ≤ 18 mmHg or clinical cardiogenic pulmonary&#xD;
             edema can be excluded&#xD;
&#xD;
          -  respiratory rate (RR) ≥ 30bpm and (or) respiratory distress&#xD;
&#xD;
          -  requiring tracheal intubation or tracheostomy for invasive mechanical ventilation&#xD;
&#xD;
          -  or have received invasive mechanical ventilation time ≤ 3 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age: &lt; 18 years old or &gt; 75 years old&#xD;
&#xD;
          -  During the early stage of the treatment, the use of mechanical ventilation for more&#xD;
             than 3 days other than ALI/ARDS for reasons&#xD;
&#xD;
          -  Lung parenchyma and airway surgery carried out within 30 days of the screening period&#xD;
&#xD;
          -  Severe arrhythmia and myocardial ischemia after cardiopulmonary resuscitation&#xD;
&#xD;
          -  Systolic blood pressure &lt; 90 mm Hg, and can not maintain its stability with&#xD;
             intravenous infusion and vasopressor drugs&#xD;
&#xD;
          -  Intubation due to interstitial lung disease (E.g., sarcoidosis, idiopathic pulmonary&#xD;
             fibrosis)&#xD;
&#xD;
          -  Any active pneumothorax or mediastinal emphysema&#xD;
&#xD;
          -  Risk factors leading to the death within 3 months in addition to ALI/ARDS during the&#xD;
             screening period (E.g., end-stage cancer)&#xD;
&#xD;
          -  Of perfluorocarbons' allergies&#xD;
&#xD;
          -  Pregnant, breastfeeding women&#xD;
&#xD;
          -  Attending other clinical trial within 30 days of the screening period&#xD;
&#xD;
          -  Severe organ dysfunction (Marshall score ≥ 3 or Sequential Organ Failure&#xD;
             Assessment（SOFA） score≥ 3, including serious liver and kidney dysfunction, upper&#xD;
             gastrointestinal hemorrhage, etc.)&#xD;
&#xD;
          -  Acute Physiology and Chronic Health Evaluation（APACHE） II score ≥ 30, high risk of&#xD;
             death&#xD;
&#xD;
          -  The researchers consider other situations not suitable for the case to participate in&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liangan Chen, M.D. PHD.</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhixin Liang, M.D.</last_name>
    <phone>86-10-13651205567</phone>
    <email>13651205567@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen Yang, M.D.</last_name>
    <phone>86-10-18618333365</phone>
    <email>ycmarcia@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>306 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Chen Liang_An</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>Perfluorocarbon</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Acute lung injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

